Diagnostic Firm Qiagen's Q3 Earnings: Analyst Says Annual Projections Attainable Despite Macro Trends

Qiagen NV's QGEN Q3 net sales of $470 million at constant exchange rates (CER) for Q3 2023 were above the outlook for at least $465 million CER, driven by 5% CER growth in the non-COVID-19 portfolio. 

Overall sales results for Q3 2023 declined 5% (-6% CER) to $476 million from Q3 2022, a period marked by significant COVID-19 sales contributions. Adjusted EPS was $0.50, beating the consensus of $0.48.

Qiagen CEO Thierry Bernard said the firm's resilient performance "was important as we work through the final quarters of COVID-19 testing headwinds from 2022 and also address an increasingly challenging macro environment."

Also Read: Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year.

Qiagen's non-COVID product sales increase of 5% at CER — to $442 million— was supported by 5% CER growth in consumables and related revenues, as well as a 3% increase in instrument sales.

The Molecular Diagnostics customer class grew 15% CER, excluding COVID-19 product groups over the 2022 quarter, led by the growth of the QuantiFERON latent TB test and growth in the Precision Medicine portfolio.

Life Sciences sales were down 4% CER due to the decline in OEM products sold to other companies during 2023.

Guidance: Qiagen affirmed its guidance for 2023 net sales of at least $1.97 billion at CER, driven by ongoing solid consumables demand, though e larger-scale instrument sales remain challenging.

The company sticks to FY23 adjusted EPS guidance of $2.07 and said QIAGEN also closely monitors fast-changing geopolitical and macro trends globally.

William Blair believes these projections are attainable, considering the sustained robust demand amidst a complex macroeconomic landscape. Moving forward, investors will be closely monitoring the factors influencing 2024 to gain a more comprehensive perspective, according to the analyst's note.

Price Action: QGEN shares are up 5.25% at $37.42 on the last check Tuesday.